SCHEMBL4749862

SCHEMBL4749862

O=S(=O)(O)c1cccc2nc[nH]c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.39
ALOX15 P16050 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PDPK1 O15530 1/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
TTR P02766 2/20 0.38
CYP1A2 P05177 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CYP2C19 P33261 1/20 0.37
FEN1 P39748 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
COMT P21964 1/20 0.33
MYC P01106 1/20 0.33
ALDH1A1 P00352 3/20 0.32
TNNI3K Q59H18 1/20 0.32
MEN1 O00255 1/20 0.32
NSD2 O96028 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246579 0.84 CA1 (0.42) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL11222595 0.82 PARP1 (0.37) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL27645647 0.80 POLB (0.49) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL338619 0.75 CYP2C19 (0.36) PARP1CYP1A2HSD17B10CYP2C19FEN1
SCHEMBL9718690 0.74 MAPK14 (0.38) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL28233407 0.73 PARP1 (0.51) PARP1TTRL3MBTL1COMTMEN1
Benzimidazole SCHEMBL1801413 0.73 PARP1 (0.42) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL1019602 0.72 QPCT (0.42) PARP1ALOX15SMN1; SMN2PDPK1CA12
SCHEMBL11222589 0.71 PARP1 (0.50) PARP1TTRCOMTMEN1POLB
SCHEMBL7196214 0.71 L3MBTL1 (0.57) TTRHSD17B10L3MBTL1MYCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008124524-A2 ARYL SULFONAMIDE COMPOUNDS AS MODULATORS OF THE CCK2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-16 WO claimed
US-20250099345-A1 UV FILTER COMPOSITIONS COMPRISING CLOSED-CELL METAL OXIDE PARTICLES BASF SE (DE) 2025-03-27 US disclosed
CN-110540523-B Method for preparing sulfo-substituted benzimidazole and derivative thereof 安徽圣诺贝化学科技有限公司 2021-02-19 CN disclosed
CN-110540523-A Method for preparing sulfo-substituted benzimidazole and derivative thereof ANHUI SHENGNUOBEI CHEMICAL TECH CO LTD 2019-12-06 CN disclosed
CN-108348421-A Personal care compositions containing cyclic carboxylic acids 荷兰联合利华有限公司 2018-07-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099345-A1 UV FILTER COMPOSITIONS COMPRISING CLOSED-CELL METAL OXIDE PARTICLES SUN2, ERCC4, XPA PARP1 2690/4885ALOX15 1326/4885SMN1; SMN2 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.